
Myriad Genetics (MYGN) Stock Forecast & Price Target
Myriad Genetics (MYGN) Analyst Ratings
Bulls say
Myriad Genetics is facing challenges, particularly in prenatal volume and Hereditary Cancer growth due to payer friction and lower revenue per test. The company lowered its guidance by $90M, indicating potential difficulties in reaching its full-year forecast. Despite strong HCT and GeneSight volumes and a refreshed sales force, the company's revenue declined and margins compressed by 460 bps year-over-year, leading to little potential for stock upside even if it meets its revenue guidance.
Bears say
Myriad Genetics is facing multiple challenges, including ongoing volume challenges and weakness in its Prenatal Health segment, which suggests that it may be losing market share or facing reduced relevance. The company's guidance has been lowered for the next few years, and its current business model may not be able to achieve profitability without divestiture of assets. While recent initiatives such as a focus on new products and an expanded sales force may help drive growth, risks to the entire medical and life science tools sector, including reduction in budgets and regulatory hurdles, may hinder the company's ability to achieve sustainable profitability. However, there is potential for upside if the company experiences a strong market adoption of existing products or a successful launch of new products.
This aggregate rating is based on analysts' research of Myriad Genetics and is not a guaranteed prediction by Public.com or investment advice.
Myriad Genetics (MYGN) Analyst Forecast & Price Prediction
Start investing in Myriad Genetics (MYGN)
Order type
Buy in
Order amount
Est. shares
0 shares